Call Us:  +1.302.777.7774

CECON logo

Log in

Login to your account

Username *
Password *
Remember Me
Show More
Add this resume to contact form Yes No
Back to Search Result GO

Drug Discovery, Early Development and Medicinal Chemistry Consultant

Technical Consultant #2421


  • Drug Discovery and Development Leader in the pharmaceutical and biotechnical Industries.
  • Deliver candidates into clinical development with focus on infectious diseases, immunology, oncology, CNS and metabolic diseases.
  • Raising venture capital and non-dilutive funding.
  • CRO and CMO landscape Program Manager, setting up partnerships and collaborations.
  • Execute complex research programs in a virtual environment.
  • Project management, timelines and budgeting.
  • Medicinal chemistry and synthesis.
  • Target validation, lead generation strategies and lead optimization.
  • Biophysical studies, assay development, ADME/PK and PKPD.
  • In vivo pharmacology and exploratory toxicology.
  • Process development, early CMC and IND-enabling studies.
  • Due diligence, intellectual property, regulatory paths and market opportunity.
  • Project and portfolio management.


Undisclosed Company, Founding Consultant, 2015 - Present

Advisory Board Member-Scientific Advisor

  • Management team Advisor for portfolio development, project strategy and due diligence.
  • Leading discovery research and development of enabling technologies for a structurally novel broad-spectrum antibiotic targeting Gram-negative pathogens.
  • Mentoring team of scientists.
  • Principal Investigator on a $ 1.25 million NIH grant.
  • Clients include a clinical-stage precision medicine oncology company and a stem-cell therapy startup targeting muscle regeneration.

Navitor Pharmaceuticals,Cambridge, MA, Director-Medicinal Chemistry, 2015 - 2017

  • Discovered NV-5138 - a first-in-class mTORC1 activator for treatment-resistant depression.
  • Delivered a clinical candidate within 3 years of target discovery.
  • Drove overall project strategy, structure-based design, medicinal chemistry, biophysics and academic collaborations.
  • Led IND-enabling studies including CMC development and non-clinical ADME.
  • Led multiple exploratory projects on the selective modulation of mTORC1 signaling for the treatment of metabolic diseases.
  • Managed internal talent and external resources in creative ways to achieve company goals.

AstraZeneca Pharmaceuticals, LP., Waltham, MA, Principal Scientist and Team Leader 2013 - 2015

  • Infection Innovative Medicines Led a chemistry team on the development of an oral small molecule treatment for RSV.
  • Led chemistry team on the discovery of improved analogs of negamycin - a translation inhibitor for the treatment of Gram-negative bacterial infections.
  • Directly supervised up to 8 reports ranging from experienced PhDs to associate chemists.

Eisai, Inc. Andover, MA, 2006 - 2012

Senior Scientist, 2010 - 2012

  • Frontier Product Creation Unit (Immunology and Inflammation) Led chemistry team in successful nomination of a first-in-class clinical candidate (E6887), a TLR7 antagonist for the treatment of systemic lupus erythematosus (SLE).

Research Investigator, 2006 - 2009

  • Discovery Chemistry (Oncology, Immunology and Atopic Diseases) Led chemistry efforts on an international project team focused on discovery of chemokine receptor antagonists.
  • Initiated a new exploratory project targeting the IL-17 pathway for psoriasis, rheumatoid arthritis and inflammatory bowel disease.
  • Key member of the team that developed second-generation analogs of eribulin (Halaven®) for expanded indications, oral bioavailability and brain penetration.

The Scripps Research Institute, La Jolla, CA, Postdoctoral Fellow, 2003 - 2006

  • Established and formalized the "On Water" process for organic synthesis, which is now widely used in diverse disciplines such as nanotechnology, material science and chemical biology.
  • Expanded the scope of click chemistry by developing a novel ruthenium-catalyzed 1,3-dipolar cycloaddition of azides and alkynes.

University of Michigan, Ann Arbor, MI, Ph.D. Organic Chemistry, 1997 - 2003

  • Devised a late-stage biaryl coupling strategy for the total synthesis of hibarimicin B. Developed novel methodology for the synthesis of 2-deoxyglycosides in natural products.

Honors & Publications


  • Business Development Fundamentals
  • Project Management for Biotechnology
  • AstraZeneca Delegate at BIO Convention and Partnering
  • Biotechnology Entrepreneur Boot Camp short course
  • Learner Player Mindsets for Managers behavioral and management training
  • Management & Skills Training Courses at Eisai (Strategic Thinking, Emotional Intelligence, Project Leadership, Regulatory Affairs).

Academic and Professional Affiliations

  • American Chemical Society-ACS
  • Global Antibiotic Research and Development Partnership - GARDP


  • Frequent peer reviewer for top journals in drug discovery, medicinal chemistry and organic chemistry.
  • Author and Co-Author of numerous publications.


  • Holds one world patent.


  • Ph.D. Organic Chemistry, University of Michigan, Ann Arbor, MI
  • M.S. Organic Chemistry, Indian Institute of Technology, Mumbai, India
  • B.S. Chemistry, University of Mumbai, Mumbai, India
Back to Search Result GO